InBioGen Co Ltd (101140) - Cash Flow Conversion Efficiency
Based on the latest financial reports, InBioGen Co Ltd (101140) has a cash flow conversion efficiency ratio of -0.010x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.67 Billion ≈ $-1.13 Million USD) by net assets (₩170.78 Billion ≈ $115.73 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 101140 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
InBioGen Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2024)
This chart illustrates how InBioGen Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.
InBioGen Co Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of InBioGen Co Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Athanase Innovation AB
ST:ATIN
|
-0.026x |
|
Purple Innovation Inc
NASDAQ:PRPL
|
-0.050x |
|
Silvano Fashion Group AS
WAR:SFG
|
0.016x |
|
Optipharm.CO.LTD
KQ:153710
|
-0.016x |
|
Dreamus Company
KQ:060570
|
0.097x |
|
Kworld Computer Co Ltd
TWO:3287
|
0.030x |
|
IGM Biosciences Inc
NASDAQ:IGMS
|
-0.503x |
|
Tinka Resources Limited
V:TK
|
-0.006x |
Annual Cash Flow Conversion Efficiency for InBioGen Co Ltd (2013–2024)
The table below shows the annual cash flow conversion efficiency of InBioGen Co Ltd from 2013 to 2024. For the full company profile with market capitalisation and key ratios, see InBioGen Co Ltd market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩159.84 Billion ≈ $108.32 Million |
₩-33.13 Million ≈ $-22.45K |
0.000x | +97.07% |
| 2023-12-31 | ₩148.68 Billion ≈ $100.76 Million |
₩-1.05 Billion ≈ $-712.04K |
-0.007x | +93.59% |
| 2022-12-31 | ₩104.42 Billion ≈ $70.76 Million |
₩-11.51 Billion ≈ $-7.80 Million |
-0.110x | -177.48% |
| 2021-12-31 | ₩178.02 Billion ≈ $120.64 Million |
₩-7.07 Billion ≈ $-4.79 Million |
-0.040x | +61.49% |
| 2020-12-31 | ₩77.91 Billion ≈ $52.80 Million |
₩-8.03 Billion ≈ $-5.44 Million |
-0.103x | -77.77% |
| 2019-12-31 | ₩66.00 Billion ≈ $44.72 Million |
₩-3.83 Billion ≈ $-2.59 Million |
-0.058x | +20.27% |
| 2018-12-31 | ₩23.35 Billion ≈ $15.83 Million |
₩-1.70 Billion ≈ $-1.15 Million |
-0.073x | -93.19% |
| 2017-12-31 | ₩11.32 Billion ≈ $7.67 Million |
₩-426.44 Million ≈ $-288.99K |
-0.038x | -162.82% |
| 2016-12-31 | ₩5.75 Billion ≈ $3.90 Million |
₩344.75 Million ≈ $233.63K |
0.060x | +104.27% |
| 2015-12-31 | ₩7.80 Billion ≈ $5.29 Million |
₩-10.96 Billion ≈ $-7.43 Million |
-1.405x | -732.60% |
| 2014-12-31 | ₩4.12 Billion ≈ $2.79 Million |
₩-695.95 Million ≈ $-471.63K |
-0.169x | +45.32% |
| 2013-12-31 | ₩3.67 Billion ≈ $2.49 Million |
₩-1.13 Billion ≈ $-767.47K |
-0.309x | -- |
About InBioGen Co Ltd
INBIOGEN Co., Ltd. engages in the manufacture and distribution of footwear products in South Korea. It is also involved in distribution of wood pellets; kiosk; and food and beverage businesses. The company was formerly known as BTONE CO.,Ltd. INBIOGEN Co., Ltd. was founded in 1949 and is headquartered in Seoul, South Korea.